Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,616.85
(
0.08%
)
US TECH 100
24,198.00
(
2.80%
)
Dow Jones
46,584.46
(
-0.18%
)
Brent Oil
94.27
(
-6.86%
)
Bitcoin
71,789.18
(
-0.28%
)
News Focus
News Focus
Post# of 257369
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122853
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 126139

Thursday, 10/13/2011 10:44:48 AM

Thursday, October 13, 2011 10:44:48 AM

Post# of 257369
ANDS reports 28-day (EVR) data in phase-2b trial of Setrobuvir (f/k/a ANA598):

http://finance.yahoo.com/news/Anadys-Announces-Positive-prnews-3498931386.html?x=0&.v=1

So far, so good, but EVR data per se don’t mean much. To date, no one has come forward to partner with ANDS on this drug, which belongs to the non-nuke class that has produced several notable duds (#msg-66814203).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today